Federal Health Minister Mustafa Kamal has directed the Drug Regulatory Authority of Pakistan (DRAP) to fast-track reforms aimed at securing the World Health Organization’s (WHO) Maturity Level 3 certification, a milestone that would align Pakistan’s pharmaceutical oversight with global standards.
Chairing a high-level meeting on Thursday, the minister underscored that achieving the WHO benchmark would enhance Pakistan’s credibility in pharmaceutical regulation, boost access to international markets, and strengthen confidence among foreign partners and investors.
“Reaching WHO Maturity Level 3 will not only strengthen our national health system but also ensure that Pakistan is recognized globally as a reliable partner in the pharmaceutical sector,” Kamal emphasized.
The meeting was attended by the Federal Secretary of Health, DRAP’s Chief Executive Officer, technical experts, and senior ministry officials. Participants were briefed on the progress of upgrading the Central Drugs Laboratory, the country’s premier medicine testing facility. Officials highlighted that international accreditation would bring Pakistan’s drug testing system in line with global best practices, ensuring stronger quality oversight of medicines in the domestic market.
Minister Kamal stressed the importance of accreditation, noting that it would guarantee the safety, quality, and efficacy of medicines while safeguarding public health. He further noted that enhancing DRAP’s capacity would pave the way for international collaborations, joint ventures with global firms, and opportunities to expand exports of locally manufactured medicines.
The minister reaffirmed the government’s commitment to transforming DRAP into a world-class regulatory authority capable of meeting modern challenges. He concluded by instructing DRAP and health ministry officials to prepare a clear roadmap with timelines to ensure both the Central Drugs Laboratory’s accreditation and WHO Maturity Level 3 status are achieved without delay.
